Detailed Information on Publication Record
2018
Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection
KARÁSEK, Petr, Natalia Anna GABŁO, Jan HLAVSA, Igor KISS, Petra VYCHYTILOVÁ et. al.Basic information
Original name
Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection
Authors
KARÁSEK, Petr (203 Czech Republic), Natalia Anna GABŁO (616 Poland, belonging to the institution), Jan HLAVSA (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic), Petra VYCHYTILOVÁ (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Vladimír PROCHÁZKA (203 Czech Republic, guarantor, belonging to the institution)
Edition
CANCER GENOMICS & PROTEOMICS, ATHENS, INT INST ANTICANCER RESEARCH, 2018, 1109-6535
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.147
RIV identification code
RIV/00216224:14110/18:00106939
Organization unit
Faculty of Medicine
UT WoS
000437932600010
Keywords in English
Pancreatic ductal adenocarcinoma; microRNAs; plasma; miR-21-5p; diagnosis; prognosis
Tags
International impact, Reviewed
Změněno: 7/3/2019 16:35, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Blood plasma microRNAs (miRNAs) are emerging as a clinically useful tool for non-invasive detection and prognosis estimation in various cancer types including pancreatic ductal adenocarcinoma (PDAC). The aim of the present study was to provide an independent validation of circulating miRNAs identified in previous studies as diagnostic and/or prognostic biomarkers in PDAC. Based on the literature search, 6 miRNAs were chosen as candidates for independent validation; miR-21-5p, miR-375, miR-155, miR-17-5p, miR-126-5p and miR-1290. Validation of these miRNAs was performed in a cohort of 25 patients with PDAC undergoing surgical resection and 24 healthy donors. Plasma levels of miRNAs were determined using quantitative real-time PCR. We confirmed significantly higher levels of all tested miRNA in blood plasma of PDAC patients in comparison to healthy controls with miR-21-5p showing the highest analytical performance (p<0.001; AUC>0.99). Increased levels of miR-21-5p (p=0.045) and miR-375 (p=0.013) were significantly associated with overall survival. Multivariate analysis demonstrated that miR-21-5p is a significant unfavorable prognostic factor independent on other clinical variables including adjuvant chemotherapy (hazard ratio 2.95; 95% CI 1.06-8.18; p=0.038). Our preliminary data indicate promising diagnostic and prognostic utility of plasma miR-21-5p in PDAC patients.
Links
| NV16-31314A, research and development project |
|